Previous 10 | Next 10 |
DiaMedica Therapeutics Inc. (DMAC) Q2 2019 Earnings Conference Call August 14, 2019 08:00 AM ET Company Participants Rick Pauls - President & CEO Scott Kellen - CFO Harry Alcorn - Chief Medical Officer Conference Call Participants Alex Nowak - Craig-Hallum Capital Tho...
DiaMedica Therapeutics (NASDAQ: DMAC ): Q2 GAAP EPS of -$0.21 beats by $0.05 . More news on: DiaMedica Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Phase Ib study of DM199 in Chronic Kidney Disease enrollment complete Encouraging early signals in mechanism biomarkers (NO and PGE2), Kidney function (eGFR) and urine albumin (UACR) Phase II CKD protocol submitted, trial initiation expected H2 2019 with interim analysis Q...
MINNEAPOLIS, Aug. 08, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its second quarter 2019 financial results will be released after the markets close on Tuesday, August 13 th . DiaMedica will host a live conference call on Wednesday, August 14 th ...
Gainers: Vislink Technologies (NASDAQ: VISL ) +316% . Attis Industries (NASDAQ: ATIS ) +32% . Valeritas Holdings (NASDAQ: VLRX ) +27% . Harmonic (NASDAQ: HLIT ) +26% . Akoustis Technologies (NASDAQ: AKTS ) +21% . SMART Global Holdings (NASDAQ: SGH ) +21% . ContraVir Pharmaceuti...
Gainers: Roan Resources (NYSE: ROAN ) +44% . Arbutus Biopharma Corporation (NASDAQ: ABUS ) +42% . China Internet Nationwide Financial Services (NASDAQ: CIFS ) +28% . DiaMedica Therapeutics (NASDAQ: DMAC ) +27% . B Communications (NASDAQ: BCOM ) +24% . Hebron Technology (NASDAQ: ...
Guardion Health Sciences (NASDAQ: GHSI ) +35% on receiving a patent from the European Union for its proprietary medical device, the MapcatSF. More news on: Guardion Health Sciences, Inc., DiaMedica Therapeutics Inc., Melinta Therapeutics, Inc., Stocks on the move, Read more .....
Favorable DM199 safety profile across tested doses Pharmacodynamic results helped identify dose range for Phase II studies Encouraging early signals in mechanism biomarkers (NO and PGE 2 ), Kidney function (eGFR) and urine albumin (UACR) Phase II trial initiation expected 2H19 wi...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you can re...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The week ahead sees Apple (AAPL) host its annual WWDC conference, Walmart (WMT) hol...
News, Short Squeeze, Breakout and More Instantly...
DiaMedica Therapeutics Inc. Company Name:
DMAC Stock Symbol:
NASDAQ Market:
DiaMedica Therapeutics Inc. Website:
Company to Host Preeclampsia Key Opinion Leader Event July 29, 2024 at 10 AM Eastern / 9 AM Central White Paper: The Potential of DM199 to Treat Preeclampsia DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel trea...
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic disease, today announced the closing of its previously announced $11.8 million private placement to accredited investors. The Company sold approximatel...
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 73.0% to $0.4585 on volume of 640,087,036 shares Ocean Power Technologies Inc. (OPTT) rose 34.9% to $0.1812 on volume of 396,326,565 shares NVIDIA Corporation (NVDA) rose 0.2% to $1...